# Allermi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allermi

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.allermi.com
- Total disclosed funding: $13M
- Latest round: Series A (Apr 2, 2024)
- Investors on record: 4

## About

Based in California, US, and founded in 2022 by CEO Shani Bocian, COO Michelle Ha, and co-founder Robert Bocian, Allermi operates as a direct-to-consumer (d2c) telehealth service provider of a personalized solution to allergy care. In March 2023, Allermi raised USD 3.5 million in seed funding led by Nelstone Ventures, with participation from FourSight Capital Partners, and Lucas Venture Group. 

Allermi provides a nasal spray kit, and medication for allergy relief, and has telemedicine offerings to patients for their treatment. The company’s kit offers salinity spray, which is a moisturizing saline nasal mist used to help patients hydrate and soothe their nasal passages. In addition, the company provides super spray, which is a powered nasal spray that combines up to four active ingredients into one bottle for patients to take allergy relief. Allermi offers a questionnaire to patients for medical history and allergy symptoms and provides customized solutions to it. The company offers mobile applications for smartphone users. 

The company generates revenue by charging for medical consultations for USD 25 yearly. Allermi charges USD 35 for nasal allergies kit monthly and USD 4.90 for shipping charges.

## Funding rounds

- Series A, Apr 2, 2024, $9.1M — Origin Ventures
- Seed, Mar 16, 2023, $3.5M — Lucas Venture Group, Nelstone Ventures, FourSight Capital Partners

## Investors

- Lucas Venture Group (https://capitalatlas.ai/funds/lucas-venture-group) — Seed
- Nelstone Ventures (https://capitalatlas.ai/funds/nelstone-ventures) — Seed
- FourSight Capital Partners (https://capitalatlas.ai/funds/foursight-capital-partners) — Seed
- Origin Ventures (https://capitalatlas.ai/funds/origin-ventures) — Series A